Eric Aboagye is Professor of Cancer Pharmacology & Molecular Imaging and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He joined the college after a PhD at the CRUK Beatson Laboratories in Glasgow, UK and post-doc fellowship at The Johns Hopkins University & Hospital in Baltimore, USA. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.
Professor Aboagye was recipient of the 2009 Sir Mackenzie Davidson Medal and was elected as a Fellow of the Academy of Medical Sciences in 2010. Academy Fellows are elected for outstanding contributions to the advancement of medical science, for innovative application of scientific knowledge or for conspicuous service to healthcare.
et al., 2023, Development and evaluation of machine learning in whole-body magnetic resonance imaging for detecting metastases in patients with lung or colon cancer: a diagnostic test accuracy study, Investigative Radiology, Vol:58, ISSN:0020-9996, Pages:823-831
et al., 2023, Radiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis., Br J Cancer
et al., 2023, Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study, European Journal of Nuclear Medicine and Molecular Imaging, Vol:50, ISSN:0340-6997, Pages:3982-3995
et al., 2023, Modulation of EGFR activity by molecularly imprinted polymer nanoparticles targeting intracellular epitopes, Nano Letters: a Journal Dedicated to Nanoscience and Nanotechnology, Vol:23, ISSN:1530-6984, Pages:9677-9682
et al., 2023, Study protocol of LANTana: A phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, United Kingdom, Bmj Open, Vol:13, ISSN:2044-6055